Ajinomoto Bio-Pharma Services Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ajinomoto Bio-Pharma Services's estimated annual revenue is currently $146.8M per year.(i)
  • Ajinomoto Bio-Pharma Services's estimated revenue per employee is $155,000

Employee Data

  • Ajinomoto Bio-Pharma Services has 947 Employees.(i)
  • Ajinomoto Bio-Pharma Services grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Ajinomoto Bio-Pharma Services?

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com

keywords:N/A

N/A

Total Funding

947

Number of Employees

$146.8M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ajinomoto Bio-Pharma Services News

2022-04-17 - 04.18.22 -- Post-COVID Supply Chain Opportunities And ...

For biopharma executives engaging with CDMOs, rethinking domestic manufacturing goes beyond supply ... Q&A | Ajinomoto Bio-Pharma Services.

2022-03-22 - Peptide Therapeutics: Contract API Manufacturing Market ...

A detailed analysis of peptide contract manufacturing service providers' ... 13therapeutics; 9 Meters Biopharma; AAPPTec; Abbiotec; Abcepta...

2021-03-30 - Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing USA - English USA - English

WETTEREN, Belgium, March 30, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manuf ...

2020-10-06 - First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services' AJIPHASE Technology Receives FDA Approval USA - English USA - English España - español Deutschland - Deutsch France - Français

TOKYO, Oct. 6, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the US FDA has approved the first commercial drug manufactured via Aji Bio-Pharma's proprie ...

2020-08-13 - Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility USA - English USA - English España - español Deutschland - Deutsch France - Français

WETTEREN, Belgium, Aug. 13, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a major expansion of small molecule manufacturing capabilities with the addition of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$488.1M9566%N/A
#2
$191.6M95727%$50M
#3
$364M963-6%N/A
#4
$242.9M9646%N/A
#5
$444.1M976-1%N/A